<DOC>
	<DOCNO>NCT00851734</DOCNO>
	<brief_summary>This first-in-man study purpose determine safety tolerability LX214 ophthalmic solution healthy volunteer patient dry eye syndrome .</brief_summary>
	<brief_title>A Dose-Escalation Study Assess Safety Tolerability LX214 Ophthalmic Solution Healthy Volunteers , Followed Open-Label Evaluation LX214 Patients With Keratoconjunctivitis Sicca ( KCS )</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>No systemic disease determine physical examination , clinical laboratory evaluation , ECG Schirmer 's I Test â‰¥ 10mm/5 minute anesthesia Corrected Snellen acuity 20/40 good eye Subjects diagnose ocular disease refraction error Subjects intraocular pressure &gt; 21 mmHg Use contact lens within 7 day prior administration first dose Subjects history ocular surgery Subjects history laser refractive surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>